Nov. 29 at 9:23 PM
$OKUR While we have to wait a few months for results the results they have posted earlier are interesting. Patient 1 had high levels of VAF per ctDNA test, but that dropped quickly. Indicating good inhibition. One reason this agent will (most likely) have lower single agent efficacy compared to others is its high selectivity for H1047R. Even if they find this mutation, not all cancer cells will have that mutation, in fact, there could be a "low" amount of mutated cells actually. So the other agents with less selectivity will inhibit mutated PI3K cells, but also cancer cells with wild-type PI3K (and therefore also healthy cells). The agent basically then acts as an aggressive agent that justs inhibits cell growths systemically but happens to also inhibit PI3K mutated cancer cells, which results in severe side effects. Therefore the only way that OKUR-219 can shine is by giving it in combination, so that the cancer gets attacked more broadly.
